GlyProVac ApS: Financial statements 2024
CVR: 39724758
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
GlyProVac ApS (CVR 39724758) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -577,426 and a net result of DKK -3,014,952 compared with DKK -2,871,688 the year before. Equity in the 2024 report amounted to DKK -653,734. The company had 5 employees in the financial year.
- Gross Profit
- DKK -577,426
- Profit/Loss
- DKK -3,014,952
- Equity
- DKK -653,734
- Total Assets
- DKK 4,390,667
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -577 t. | -3 mio. | -654 t. | 5 |
| 2023 | - | -815 t. | -2.9 mio. | 852 t. | 4 |
| 2022 | - | 1.3 mio. | -633 t. | 5 mio. | 4 |
| 2021 | - | 993 t. | -487 t. | 2.4 mio. | 3 |
| 2020 | - | 1.1 mio. | -699 t. | 672 t. | 4 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout GlyProVac ApS
GlyProVac ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Anders Boysen and Ann Zahle Andersen. The board consists of Ann Zahle Andersen (chair), Allan Rosetzsky, Kirsten Winther and Willem Adriaan de Jongh. The company's owners include Bente Kristiansen, Rossi Finans ApS and I/S Rødeledsvej. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -2,128,863 and a net result of DKK -5,168,999 compared with DKK -3,014,952 the year before. Equity in the 2025 report amounted to DKK -831,720.